NASDAQ, VRUS - Pharmasset
We are a clinical-stage pharmaceutical company committed to discovering,
developing and commercializing novel drugs to treat viral infections. Our
primary focus is on the development of oral therapeutics for the treatment of
hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency
virus, or HIV. Our research and development efforts focus on a class of
compounds known as nucleoside analogs, which act to inhibit the natural enzymes
required for viral replication. We are currently focusing on three product
candidates, two of which we are developing ourselves and one of which we are
developing with a strategic partner:
? Clevudine, for the treatment of chronic HBV infection, is enrolling Phase
3 clinical trials for registration in North, Central and South America
(?the Americas?) and Europe;
? R7128, a pro-drug of PSI-6130 for the treatment of HCV, in Part 3 ...
Read SEC Filing on NASDAQ.com »